ANAFRANIL RETARD

Main information

  • Trade name:
  • ANAFRANIL RETARD 75 mg prolonged-release tablet
  • Dosage:
  • 75 mg
  • Pharmaceutical form:
  • prolonged-release tablet
  • Prescription type:
  • Prescription only
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ANAFRANIL RETARD 75 mg prolonged-release tablet
    Finland
  • Language:
  • English

Therapeutic information

  • Therapeutic area:
  • Clomipramine
  • Product summary:
  • ; Suitability for use in older adult patients Clomipramini hydrochloridum Avoid using in older persons. Anticholinergic. Sedative. Serotonergic. Risk of QT prolongation. Significant adverse effects include confusion, cognitive disorder, tremor, tachycardia, orthostatic hypotension and serotonin syndrome. Increases risk for falls. Take several interactions into account. Weakens the efficacy of anti-Alzheimer´s drugs.

Status

  • Source:
  • Fimea
  • Authorization status:
  • Marketing authorization granted
  • Authorization number:
  • 8990
  • Authorization date:
  • 11-12-2007
  • Last update:
  • 26-07-2018